Skip to main content
. Author manuscript; available in PMC: 2013 Jun 28.
Published in final edited form as: Cancer Lett. 2012 Jan 17;319(2):136–143. doi: 10.1016/j.canlet.2011.12.042

Fig. 2.

Fig. 2

Plasma stability, plasma clearance and tumor uptake of Bac-ELP-H1. (A) Stability of the rhodamine label on Bac-ELP-H1-Rho was determined by incubation in fresh mouse plasma at 37 °C, thermal precipitation of the labeled polypeptide, and spectrophotometric detection of released label in the remaining plasma. Bars, s.d. (B) Plasma levels with time following IV or IP injection of Bac-ELP1-H1-Rho. Data represent the mean ± s.d. of 6 animals per group. (C) Representative images of tumor sections 3 h after IV or IP injection of rhodamine-labeled Bac-ELP1-H1. The perfused vasculature was marked by infusion of high molecular weight dextran 1 min prior to euthanasia (top panel), and rhodamine fluorescence was used to follow the localization of the polypeptide within the tumor (middle panel). (D) Bac-ELP1-H1-Rho tumor levels 3 h after IV or IP administration of rhodamine-labeled Bac-ELP1-H1 with and without tumor hyperthermia. Bars, s.e. (E) Bac-ELP1-H1-Rho and Bac-ELP2-H1-Rho tumor levels 3 h after IV administration of polypeptides with or without hyperthermia. Bars, s.e. (F) High magnification images of the tumors in C were obtained using a fluorescence microscope and a 40 × objective. Cell nuclei were stained with Hoechst 33342.